117 related articles for article (PubMed ID: 33999735)
1. A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?
Dintsios CM
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):283-297. PubMed ID: 33999735
[TBL] [Abstract][Full Text] [Related]
2. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
3. Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree.
Dintsios CM; Worm F; Ruof J; Herpers M
Health Econ Rev; 2019 Dec; 9(1):35. PubMed ID: 31848760
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
Lauenroth VD; Stargardt T
Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
[TBL] [Abstract][Full Text] [Related]
5. Predictors of negotiated prices for new drugs in Germany.
Gandjour A; Schüßler S; Hammerschmidt T; Dintsios CM
Eur J Health Econ; 2020 Sep; 21(7):1049-1057. PubMed ID: 32451745
[TBL] [Abstract][Full Text] [Related]
6. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of Late AMNOG Benefit Assessments].
Rieder V; Hammerschmidt T
Gesundheitswesen; 2018 Aug; 80(8-09):e44-e53. PubMed ID: 29698986
[TBL] [Abstract][Full Text] [Related]
8. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
Blome C; Augustin M; Metin H; Lohrberg D
Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
[TBL] [Abstract][Full Text] [Related]
9. Determinants of Orphan Drug Prices in Germany.
Worm F; Dintsios CM
Pharmacoeconomics; 2020 Apr; 38(4):397-411. PubMed ID: 31903523
[TBL] [Abstract][Full Text] [Related]
10. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.
Dintsios CM; Beinhauer I
Health Econ Rev; 2020 Mar; 10(1):7. PubMed ID: 32172494
[TBL] [Abstract][Full Text] [Related]
11. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
Hörn H; Nink K; McGauran N; Wieseler B
Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
[TBL] [Abstract][Full Text] [Related]
12. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
Peinemann F; Labeit A
J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
[TBL] [Abstract][Full Text] [Related]
13. German Pharmaceutical Pricing: Lessons for the United States.
Rodwin MA; Gerke S
Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
[TBL] [Abstract][Full Text] [Related]
14. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
Kleining K; Laufenberg J; Thrun P; Ehlert D; Wasem J; Bartol A
Health Econ Policy Law; 2023 Aug; ():1-18. PubMed ID: 37577932
[TBL] [Abstract][Full Text] [Related]
15. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
17. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
[TBL] [Abstract][Full Text] [Related]
18. [Involvement of scientific societies in early benefit assessment: Simulated participation or valuable additional input?].
Bleß HH; Seidlitz C; Ohlmeier C; de Millas C
Z Evid Fortbild Qual Gesundhwes; 2018 Feb; 130():49-57. PubMed ID: 29103831
[TBL] [Abstract][Full Text] [Related]
19. The Impact Of Price Regulation On The Availability Of New Drugs In Germany.
Stern AD; Pietrulla F; Herr A; Kesselheim AS; Sarpatwari A
Health Aff (Millwood); 2019 Jul; 38(7):1182-1187. PubMed ID: 31260362
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
